Insider · CIK 0001478037
Zein Abdalla
director
Files at CTSH (COGNIZANT TECHNOLOGY SOLUTIONS CORP). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 4, 2025 | CTSH COGNIZANT TECHNOLOGY SOLUTIONS CORP | MOption exercise Class A Common Stock | +3,417 | - | - | 22,560 | Jun 5, 2025 |
| Jun 3, 2025 | CTSH COGNIZANT TECHNOLOGY SOLUTIONS CORP | AGrant or award Restricted Stock Unitsderivative | +2,863 | $0.00 | $0 | 2,863 | Jun 5, 2025 |
| Jun 4, 2025 | CTSH COGNIZANT TECHNOLOGY SOLUTIONS CORP | FTax withholding Class A Common Stock | -29 | $80.32 | $2,329 | 22,531 | Jun 5, 2025 |
| Jun 4, 2025 | CTSH COGNIZANT TECHNOLOGY SOLUTIONS CORP | MOption exercise Restricted Stock Unitsderivative | -3,417 | $0.00 | $0 | 0 | Jun 5, 2025 |
| Jun 4, 2025 | CTSH COGNIZANT TECHNOLOGY SOLUTIONS CORP | DDisposition to issuer Restricted Stock Unitsderivative | -0 | $80.32 | $24 | 0 | Jun 5, 2025 |
| May 28, 2025 | CTSH COGNIZANT TECHNOLOGY SOLUTIONS CORP | AGrant or award Restricted Stock Unitsderivative | +13 | $0.00 | $0 | 3,417 | May 30, 2025 |
| Feb 26, 2025 | CTSH COGNIZANT TECHNOLOGY SOLUTIONS CORP | AGrant or award Restricted Stock Unitsderivative | +12 | $0.00 | $0 | 3,404 | Feb 28, 2025 |
| Nov 27, 2024 | CTSH COGNIZANT TECHNOLOGY SOLUTIONS CORP | AGrant or award Restricted Stock Unitsderivative | +13 | $0.00 | $0 | 3,392 | Dec 2, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.